So now that Olinvyk has been approved
"What's next?"
Trevena has plenty to do during the next few months as you can see in the photo below:
Sources of Quotes
"What's next?"
Trevena has plenty to do during the next few months as you can see in the photo below:
Sources of Quotes
Also from that same interview, Trevena's spokesperson stated that,
"As the opioid addiction crisis continues and the FDA works to help stem it, drugmakers who were sued for hundreds of millions by city and state governments over marketing claims continue to settle. The results are massive billion-dollar payouts, often followed by bankruptcy proceedings.”
Massive, Billion-Dollar Payouts … often followed by bankruptcy. This creates more space for Olinvyk to enter the market. Established IV opiods will still be used. However, it is also likely doctors will use a combination of them INCLUDING Olinvyk. Depending on the surgery, some doctors may only need Olinvyk. It is a all a case-by-case basis. Olinvyk doesn’t need to take over any pre-existing opioid to be successful and reach billions in annual sales.
"As the opioid addiction crisis continues and the FDA works to help stem it, drugmakers who were sued for hundreds of millions by city and state governments over marketing claims continue to settle. The results are massive billion-dollar payouts, often followed by bankruptcy proceedings.”
Massive, Billion-Dollar Payouts … often followed by bankruptcy. This creates more space for Olinvyk to enter the market. Established IV opiods will still be used. However, it is also likely doctors will use a combination of them INCLUDING Olinvyk. Depending on the surgery, some doctors may only need Olinvyk. It is a all a case-by-case basis. Olinvyk doesn’t need to take over any pre-existing opioid to be successful and reach billions in annual sales.
"What do I get for waiting?"
Q: What do I get for waiting
A: One opinion is between $61.13 to $110.03 a share. Q: How long would it take to get to that value? . A: As long as necessary to fulfill that thesis (i.e. $1.5B high risk patients + licensing revenue from sales in China, S. Korea, and all the other countries entering into a licensing agreement w/ Trevena. Q: I think that $$61.13/share is too high! A: Chop it in half. Are you okay with $30+/share? Q: I think that is still too high! A: Chop it in half again. Are you okay w/ $15+/share? Q: I think that is still too high! A: Well, sell it and go buy something else ... or ... y o u c o u l d b e p a t i e n t . Note: Patient could be 1 year. That's 4 earnings quarters. The share price is a $1.50 now. $15+/share 1 year later = 10x (aka 1,000%) That would be better than TSLA or NIO. Maybe. Nothing is guaranteed. That's why you are here and not "invested" in a CD earning <1% |
Q: I think that is too low!
A: Well, it might be once the "Initial core focus" market has been successfully penetrated (approx. 15M days of therapy = $1.5B+ market opportunity) and then Trevena moves into it target "Expanded areas of focus" estimated at $28M. Additionally, Trevena has a number of other assists in its pipeline in collaboration with a number of high-profile institutions such as the Imperial College London, the National Institute on Drug Abuse, and the National Institute of Health. |
"I don't think the team at Trevena will be successful. They don't have enough experience!"
"I don't think Trevena has sufficient funds to be successful"
"I don't see what is so special about Olinvyk"
"I still have more questions. Where can I find some answers?"
"Okay, I don't have anymore questions but I can't sleep."
Answer: Go to YouTube.com and watch any one of the pages and pages of science and keynote addresses by Robert Lefkowitz.
Answer: Go to YouTube.com and watch any one of the pages and pages of science and keynote addresses by Robert Lefkowitz.
"How can I learn how to value a Biotech company myself?"
If you are confident with your valuation, post to me on StockTwits @WhidbeyIslandWA and I'll add your analysis here.
If you are confident with your valuation, post to me on StockTwits @WhidbeyIslandWA and I'll add your analysis here.
Random Timeline Between when Trevena was almost delisted from NASDAQ until present ...
Early 2020 ...
Note: On May 26, 2020, Trevena, Inc. (the “Company”) received notice from Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market confirming that the Staff has determined that for the last 10 consecutive business days, from May 11 to May 22, 2020, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Staff has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and it has indicated to the Company that this matter is now closed.
Late October 2021 ...